As for hematological malignancies, the FGFR1/2/3 inhibitor pemigatinib has shown impressive efficacy in a small registration-directed trial in patients with FGFR1-rearranged myeloid/lymphoid neoplasms [193]. The gene discussed is FGFR1; the disease is hematologic disorder.